FT836 CAR T-cells plus daratumumab for relapsed/refractory myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new type of cell therapy (FT836 CAR T-cells) combined with the drug daratumumab for people with multiple myeloma that has come back or not responded to at least 3 prior treatments. The goal is to see if this combination can help fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 79 years old.
- You must have tried at least 3 different types of myeloma treatments and your cancer got worse during or within 60 days of your last treatment.
- You need to have measurable disease, meaning specific protein levels in your blood or urine that can be tracked.
- You must be in generally good health, with enough kidney, liver, heart, and lung function. Your doctor will check this with blood tests and scans.
- You cannot have certain other medical conditions like active infections, HIV, hepatitis B or C, or a history of severe autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests an experimental CAR T-cell treatment that targets BCMA in people with relapsed or refractory multiple myeloma. It may help shrink the cancer after it has not responded to several prior therapies.
This trial tests a new cell therapy (CAR-T) that targets two proteins on myeloma cells for patients whose cancer has returned or not responded after at least three prior treatments. It aims to see if this therapy is safe and effective.
This trial tests a new type of immune cell therapy (called CAR T-cells) designed to treat advanced multiple myeloma that has not responded well to standard treatments. The study focuses on safety and how well your body tolerates this personalized cell therapy.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (BCMA and FcRL5) on myeloma cells. It is for people whose myeloma has returned or not responded to other treatments.
This trial tests a new dual-targeted cell therapy (AZD0120) against standard regimens for people with multiple myeloma that has come back or not responded to treatment. It aims to see if the new therapy works better than standard options.
Hear when a new Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.